Synopsis: Rossari Biotech Limited reported a strong Q4 FY26 performance, with revenue rising to Rs. 703.9 crore (21.1% YoY) and net profit increasing to Rs. 46 crore up by (33.5% YoY). The company also announced a final dividend of Rs. 0.50 per share (25%), reflecting steady financial performance and shareholder returns.
Rossari Biotech, a leading specialty chemicals manufacturer, continues to strengthen its position across key segments such as home & personal care, performance chemicals, and animal health & nutrition. The company has been focusing on expanding its product portfolio while maintaining cost efficiency. Its consistent growth across segments has helped it deliver stable financial performance despite raw material cost fluctuations.
As of April 2026, Rossari Biotech shares are trading at Rs. 480, with a market capitalization of Rs. 2,657 crore and the stock shows decrease of 5.40% in their price as compared to previous close of Rs. 504.
The stock has recorded a 52-week high of Rs. 768 and a low of Rs. 373, indicating volatility but also recovery from lower levels. The company trades at a P/E ratio of 17.8, suggesting relatively reasonable valuation compared to peeRs. Its ROCE stands at 14.6% and ROE at 11.8%, indicating moderate capital efficiency.
During Q3 FY26 (December 2025 quarter), the company reported revenue of Rs. 582.2 crore, while net profit stood at Rs. 32.8 crore. Operating profit came in at Rs. 68.9 crore, with an operating margin of 11.84%, indicating stable operational performance. Profit before tax was Rs. 42.1 crore, reflecting steady earnings despite cost pressures.
In Q4 FY26 (March 2026 quarter), Rossari Biotech delivered a strong improvement compared to Q3. Revenue increased to Rs. 703.9 crore from Rs. 582.2 crore, marking a 21% sequential growth, while net profit rose to Rs. 46 crore from Rs. 32.8 crore, reflecting a 40% QoQ increase. Operating profit improved to Rs. 77.3 crore, with margins at 11.28%, slightly lower than Q3 due to cost factors, but overall profitability improved due to higher scale. Profit before tax increased significantly to Rs. 63.7 crore, compared to Rs. 42.1 crore in Q3.
The company has recommended a final dividend of Rs. 0.50 per share (25%) for FY26, subject to shareholder approval. This reflects management’s confidence in steady cash flows and commitment to rewarding shareholders.
Rossari Biotech has delivered a strong Q4 FY26 performance, with notable growth in both revenue and profitability compared to Q3. The company’s ability to scale revenue while maintaining stable margins highlights operational strength.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Rossari Biotech Falls 5% Despite 33% Rise in Q4 Profit; Revenue Crosses ₹700 Cr appeared first on Trade Brains.